JACC: Cardiovascular Interventions
Volume 3, Issue 2 , Pages 203-212 , February 2010

Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention: A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)

  • Gilles Montalescot, MD, PhD

      Affiliations

    • Pitiè-Salpêtrière University Hospital, Paris, France
    • Corresponding Author InformationReprint requests and correspondence: Dr. Gilles Montalescot, Institut de Cardiologie, INSERM U937, 47 Boulevard de l'Hôpital, 75013 Paris, France
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Mark A. de Belder, MD

      Affiliations

    • The James Cook University Hospital, Middlesbrough, United Kingdom
    • ,
  • Luc Janssens, MD

      Affiliations

    • AZ Imelda Ziekenhuis, Bonheiden, Belgium
    • ,
  • Olivier Katz, MD

      Affiliations

    • Clinique Saint-Joseph, Colmar, France
    • ,
  • Wladyslaw Pluta, MD

      Affiliations

    • Wojewodzkie Centrum Medyczne, Opole, Poland
    • ,
  • Patrick Ecollan, MD

      Affiliations

    • Pitiè-Salpêtrière University Hospital, Paris, France
    • ,
  • Michal Tendera, MD

      Affiliations

    • Medical University of Silesia, Katowice, Poland
    • ,
  • Ad J. van Boven, MD

      Affiliations

    • Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands
    • ,
  • Petr Widimsky, MD

      Affiliations

    • University Hospital FN Kralovske Vinohrady, Prague, Czech Republic
    • ,
  • Henning R. Andersen, MD

      Affiliations

    • Skejby University Hospital, Aarhus, Denmark
    • ,
  • Amadeo Betriu, MD

      Affiliations

    • Hospital Clinic I Provincial, Barcelona, Spain
    • ,
  • Paul Armstrong, MD

      Affiliations

    • University of Alberta Hospital, Edmonton, Alberta, Canada
    • ,
  • Bruce R. Brodie, MD

      Affiliations

    • LeBauer Cardiovascular Research, Greensboro, North Carolina
    • ,
  • Howard C. Herrmann, MD

      Affiliations

    • University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
    • ,
  • Franz-Josef Neumann, MD

      Affiliations

    • Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
    • ,
  • Mark B. Effron, MD

      Affiliations

    • Eli Lilly and Company, Indianapolis, Indiana
    • ,
  • Jiandong Lu, PhD

      Affiliations

    • Centocor Research and Development, Inc., Malvern, Pennsylvania
    • ,
  • Elliot S. Barnathan, MD

      Affiliations

    • Centocor Research and Development, Inc., Malvern, Pennsylvania
    • ,
  • Eric J. Topol, MD

      Affiliations

    • The Scripps Research Institute and Scripps Clinic, La Jolla, California
    • ,
  • FINESSE Investigators

Received 13 July 2009 ,Revised 19 October 2009 ,Accepted 13 November 2009.

References 

  1. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:576S–599S
  2. Silber S, Albertsson P, Aviles FF, et al. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Guidelines for percutaneous coronary interventions. Eur Heart J. 2005;26:804–847
  3. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary (A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty)). J Am Coll Cardiol. 2001;37:2215–2238
  4. Montalescot G, Bal-dit-Sollier C, Chibedi D, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003;91:925–930
  5. Montalescot G, Philippe F, Ankri A, et al. French Investigators of the ESSENCE Trial Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation. 1998;98:294–299
  6. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256
  7. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006–1017
  8. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med. 2007;167:2423–2430
  9. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  10. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–2086
  11. Labeque JN, Jais C, Dubos O, et al. Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv. 2006;67:207–213
  12. Montalescot G, Ongen Z, Guindy R, et al. Predictors of outcome in patients undergoing PCI (Results of the RIVIERA study). Int J Cardiol. 2008;129:379–387
  13. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–2217
  14. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004;147:E16
  15. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–723
  16. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  17. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994–998
  18. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961–966
  19. Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005;60:364–373
  20. Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49:2238–2246
  21. Zeymer U, Gitt A, Junger C, et al. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. Thromb Haemost. 2008;99:150–154
  22. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J. 2005;150:116–122
  23. Welsh RC, Gordon P, Westerhout CM, Buller CE, O'Neill B, Armstrong PW. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv. 2007;70:341–348
  24. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759–1765
  25. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28:443–449
  26. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–2230
  27. Collet JP, Montalescot G, Agnelli G, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes (The Global Registry of Acute Coronary Events). Eur Heart J. 2005;26:2285–2293
  28. Danchin N, Collet J, Marco J. Use of low molecular weight heparin is associated with improved in-hospital survival of ST-elevation myocardial infarction patients who receive reperfusion therapy: Results from the nationwide French FAST-MI registry. In: Presented at: ACC Scientific Sessions. New Orleans, LA. March 24–27, 2007;
  29. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391–394
  30. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J. 2005;26:440–446

 This work was supported by Centocor, Inc., Malvern, Pennsylvania, and Eli Lilly, Indianapolis, Indiana. Dr. Montalescot reports receiving consulting fees, speaking fees, and research grant support from Eli Lilly and Sanofi-Aventis. Dr. Ellis reports being employed and Dr. Topol reports having been employed by the Cleveland Clinic, which received research funds from Eli Lilly and Centocor to assist in the coordination of this study. Dr. de Belder reports receiving advisory board fees from Eli Lilly, fees provided for the United Kingdom coordination of the FINESSE trial, and lecture fees from Eli Lilly. Dr. Armstrong reports receiving research grants from Schering-Plough, Boehringer Ingelheim, and Hoffmann-La Roche. Dr. Effron reports being employed by Eli Lilly. Dr. Widimsky reports receiving consulting fees and speaking fees from Eli Lilly. Dr. Andersen reports receiving speaking fees and research grants from Eli Lilly. Dr. Herrmann reports receiving speaking fees from Schering-Plough and research grants from the Medicines Company, Conor Medsystems, and Schering-Plough. Drs. Barnathan and Lu report being employed by Centocor.

PII: S1936-8798(09)00832-2

doi: 10.1016/j.jcin.2009.11.012

JACC: Cardiovascular Interventions
Volume 3, Issue 2 , Pages 203-212 , February 2010

Article Tools

* Image Usage & Resolution